In this clinical trial, patients with lichen planopilaris treated with the oral TYK2 inhibitor deucravacitinib showed significant improvement in PGA, LPPAI, and Skindex-16 scores over 24 weeks, with transcriptomic analyses indicating decreased inflammatory and immune pathway activity post-treatment.
5 citations
,
July 2023 in “International Journal of Women’s Dermatology” This study reports that anifrolumab showed promising improvement in a case of refractory discoid lupus erythematosus, specifically enhancing skin lesions and promoting hair regrowth, suggesting potential as an effective therapy for severe cases.
1 citations
,
May 2025 in “The Journal of Rheumatology” In this case report, treatment with anifrolumab led to significant improvement in symptoms for a 52-year-old woman with refractory systemic lupus erythematosus, including resolution of chronic lupus headaches resistant to previous therapies.
4 citations
,
January 2012 in “Chemical Immunology” This paper discusses the challenges of diagnosing drug eruptions, emphasizing the nonspecific patterns and unclear pathomechanisms, and calls for further research using new biologic drugs to understand these reactions better.
5 citations
,
February 2022 in “Seminars in cell & developmental biology” This review discusses the complexities of hidradenitis suppurativa pathogenesis, highlighting issues with Notch signaling, immune dysregulation, and the role of keratinocytes and ECM, but reports no new clinical results.